entertainment -WSS

entertainment

author：hotspot 2025-09-30 17:44:39 - browse：9

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： CVS Caremark has created a new ploy: the drug ‘rebate credit’

knowledge

hotspot

WSS

Drug for rare kidney disease narrowly misses mark in clinical trial

Baby aspirin cuts fat buildup in liver disease patients, in small study

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Readout Newsletter: Bluebird, CVS, Contineum

UnitedHealth increases loan offers after Change Healthcare outage

Positive childhood experiences can help future health

hotspot

entertainment

focus

Duchenne breakthrough therapy leaves behind pioneering families

App could help diagnose ear infections more accurately — and at home

Jerome Adams on the need for new antivirals for Covid

Experts study whether long Covid risk adds up with each reinfection

In Memoriam: Notable people who died in 2023

Neuroscience’s long legacy of racism

After affirmative action ruling, medical educators look to 'holistic review'

Virtual Event: March of the Biosimilars

At least 13 dead in Texas as scorching temps continue

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

entertainment

CDC's new outbreak response network to include Northeastern

Virtual Event: March of the Biosimilars

FDA panel to weigh approval of NurOwn, controversial ALS drug

Readout Newsletter: Bluebird, CVS, Contineum

Senators: Long

Drug for rare kidney disease narrowly misses mark in clinical trial

Wikipedia

knowledge

hotspot

hotspot